Page last updated: 2024-12-10

1,3-dimethyl-8-[2-(1-pyrrolidinyl)ethylthio]-6-sulfanylidene-7H-purin-2-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

The compound you describe, **1,3-dimethyl-8-[2-(1-pyrrolidinyl)ethylthio]-6-sulfanylidene-7H-purin-2-one**, is an interesting molecule with potential applications in research, particularly in the field of **pharmacology and medicinal chemistry**.

Here's a breakdown of its components and potential importance:

**Structure:**

* **Purine-2-one:** This is a core structure found in many biologically important molecules, including caffeine and theobromine. It's a modified purine base with a ketone group at position 2.
* **1,3-dimethyl:** This indicates the presence of two methyl groups (CH3) attached to positions 1 and 3 of the purine ring. These methyl groups likely influence the molecule's overall shape and interactions with biological targets.
* **8-[2-(1-pyrrolidinyl)ethylthio]:** This complex side chain attached to position 8 of the purine ring contains a pyrrolidine ring (a 5-membered ring with a nitrogen atom) connected to an ethyl group, which is then linked to a sulfur atom. The presence of the pyrrolidine ring suggests possible interactions with specific receptor sites.
* **6-sulfanylidene:** This indicates a sulfur atom doubly bonded to position 6 of the purine ring. The sulfur atom could contribute to interactions with enzymes or other proteins.

**Potential Research Applications:**

1. **Antiviral Activity:** The presence of the purine-2-one core and the specific side chain structure suggest a potential for antiviral activity. Purines are known to interact with viral nucleic acids and enzymes, and modifications to the structure can lead to selective inhibition of viral replication.

2. **Anti-inflammatory Activity:** The sulfur atom and pyrrolidine ring could contribute to anti-inflammatory activity by modulating the activity of enzymes involved in the inflammatory cascade.

3. **Cancer Research:** Purines are known to be involved in cell signaling and regulation, and modifications like those found in this molecule could potentially target specific pathways involved in cancer cell growth and proliferation.

4. **Pharmacological Tool:** The compound could be used as a probe to investigate the role of purine receptors in various biological processes. It could help researchers understand how purines interact with specific receptors and how this interaction affects different cellular functions.

**Note:** It's important to remember that the specific biological activity of this molecule and its potential applications remain to be fully investigated. More research is needed to understand its precise mechanism of action and its potential therapeutic benefits.

This information is for educational purposes and should not be considered medical advice.

Cross-References

ID SourceID
PubMed CID3034554
CHEMBL ID1494615
CHEBI ID109390

Synonyms (42)

Synonym
NCI60_042234
1,3-dimethyl-8-((2-(1-pyrrolidinyl)ethyl)thio)-6-thioxo-1,3,6,9-tetrahydro-2h-purin-2-one
NCGC00014035
mls000737206 ,
uric acid,3-dimethyl-8-[(2-pyrrolidinoethyl)thio]-6-thio-
6-thio-[8-(.beta.-n-pyrrolidinoethyl)thio]theophylline
6559-86-0
nsc-99657
theophylline, 8-[(2-pyrrolidinoethyl)thio]-6-thio-
theophylline, 8-[[2-(1-pyrrolidinyl)ethyl]thio]-6-thio-
nsc99657 ,
smr000528466
NCI99657
uric acid, 1,3-dimethyl-8-(2-pyrrolidinoethyl)thio-6-thio-
theophylline, 8-(2-pyrrolidinoethyl)thio-6-thio-
theophylline, 8-((2-(1-pyrrolidinyl)ethyl)thio)-6-thio-
nsc 99657
6-thio-8-(beta-n-pyrrolidinoethyl)thiotheophylline
theophylline, 8-((2-pyrrolidinoethyl)thio)-6-thio-
brn 1155144
NCISTRUC1_001373
NCISTRUC2_001120
NCGC00097144-01
CHEBI:109390
1,3-dimethyl-8-(2-pyrrolidin-1-ylethylsulfanyl)-6-sulfanylidene-7h-purin-2-one
1,3,6,9-tetrahydro-1,3-dimethyl-8-((2-(1-pyrrolidinyl)ethyl)thio)-6-thioxo-2h-purin-2-one
unii-z451pds8p0
z451pds8p0 ,
CCG-36654
NCGC00014035-02
CHEMBL1494615
cid_3034554
1,3-dimethyl-8-[2-(1-pyrrolidinyl)ethylthio]-6-sulfanylidene-7h-purin-2-one
bdbm55874
1,3-dimethyl-8-(2-pyrrolidinoethylthio)-6-thioxo-7h-purin-2-one
Q27188509
DTXSID80215852
1,3-dimethyl-8-{[2-(pyrrolidin-1-yl)ethyl]sulfanyl}-6-sulfanylidene-1,3,6,9-tetrahydro-2h-purin-2-one
m0s ,
2h-purin-2-one, 1,3,6,9-tetrahydro-1,3-dimethyl-8-((2-(1-pyrrolidinyl)ethyl)thio)-6-thioxo-
2h-purin-2-one, 1,3,6,7-tetrahydro-1,3-dimethyl-8-((2-(1-pyrrolidinyl)ethyl)thio)-6-thioxo-
ja2-4 (nsc99657)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oxopurine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency44.66840.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency11.22020.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency22.38720.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency3.54810.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency5.62340.01846.806014.1254AID624417
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency6.51040.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency21.85280.000811.382244.6684AID686978; AID686979
thioredoxin glutathione reductaseSchistosoma mansoniPotency39.81070.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency4.46680.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency8.91250.707912.194339.8107AID720542
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
beta-2 adrenergic receptorHomo sapiens (human)Potency15.84890.00586.026332.6427AID492947
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency28.18380.036619.637650.1187AID2100
cytochrome P450 2C9 precursorHomo sapiens (human)Potency3.16230.00636.904339.8107AID883
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency79.43280.354828.065989.1251AID504847
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency15.84890.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency2.49060.00798.23321,122.0200AID2546; AID2551
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency28.18380.00419.962528.1838AID2675
relaxin receptor 1 isoform 1Homo sapiens (human)Potency22.38720.038814.350143.6206AID2676
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency3.98110.025911.239831.6228AID602313
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency3.16230.00638.235039.8107AID883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
neutrophil cytosol factor 1Homo sapiens (human)IC50 (µMol)50.00000.39006.544129.1200AID1275
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]